"Lebrikizumab Clears Eczema Skin Rapidly, Safely" - Kevin Kunzmann
Novel monoclonal antibody lebrikizumab was shown to significantly benefit adults with moderate to severe atopic dermatitis (eczema) in new phase 2b data evidencing the interleukin 13 (IL-13)-targeting therapy.
Press Release
New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results
Dec 09, 2022 View All Press Releases